Replies to post #3781 on Biotech Values

[winchem21]

>> Can anything about the progress of the other phase 2 clinical trials be deduced by virtue of the fact that GENR has started the last phase 2 trial? <<

The 10 mg dose was added based on initial results of the other phase 2 trials. One can reasonably infer some of the early phase II data indicate efficacy at the 10 mg level. Lower doses minimize systemic side effect concerns and also lessen the amount of squalamine needed for phase III trials...

wc21